Can-Fite

Can-Fite BioPharma Ltd. is a pioneering Israeli biotechnology company specializing in the development of small molecule drugs that target A3 adenosine receptors (A3AR) for the treatment of inflammatory diseases, cancer, and liver disorders. With a strategic focus on significant unmet medical needs, Can-Fite's leading drug candidates include Piclidenoson, which is in advanced clinical trials for psoriasis and rheumatoid arthritis, and Namodenoson, currently undergoing trials for hepatocellular carcinoma (liver cancer) and non-alcoholic steatohepatitis (NASH). Leveraging its proprietary technology platform and extensive clinical research capabilities, Can-Fite aims to bring innovative and effective therapies to market, enhancing patient care and outcomes globally  

Can-Fite BioPharma Ltd. has a robust pipeline of small molecule drugs that target A3 adenosine receptors (A3AR) to treat inflammatory, oncological, and liver diseases. Here's a review of their key drug candidates:

1. Piclidenoson (CF101)

• Indications: Psoriasis, Rheumatoid Arthritis
• Development Stage: Phase III clinical trials for both indications.
• Details: Piclidenoson is an oral anti-inflammatory drug designed to treat autoimmune diseases. It has demonstrated efficacy in reducing inflammation and disease symptoms in patients with psoriasis and rheumatoid arthritis.

2. Namodenoson (CF102)

• Indications: Hepatocellular Carcinoma (HCC), Non-Alcoholic Steatohepatitis (NASH)
• Development Stage: Phase IIb for NASH, Phase III for HCC.
• Details: Namodenoson is an oral drug that has shown potential in treating liver cancer and NASH by inducing cancer cell apoptosis and reducing liver fat and inflammation. It has been granted Orphan Drug Designation and Fast Track status by the FDA for liver cancer treatment.

3. CF602

• Indication: Erectile Dysfunction
• Development Stage: Preclinical
• Details: CF602 is designed to treat erectile dysfunction by targeting the A3AR, which has shown promising results in preclinical studies.

4. Cannabinoid Compounds

• Indication: Various inflammatory conditions
• Development Stage: Preclinical
• Details: Can-Fite is exploring the therapeutic potential of cannabinoids in targeting inflammatory pathways, leveraging their proprietary platform technology.

Strategic Advantages

• Proprietary Technology: Can-Fite’s focus on A3AR as a therapeutic target is a key differentiator, as these receptors are highly expressed in inflammatory and cancerous tissues but low in normal tissues, potentially leading to high efficacy with minimal side effects.
• Clinical Experience: The company has conducted extensive clinical trials, with over 1,500 patients having participated, demonstrating the safety and potential efficacy of their drug candidates.
• Regulatory Designations: Namodenoson’s Orphan Drug and Fast Track designations highlight the promise and potential expedited development pathway for their treatments.